Truist Securities Maintains Buy on PROCEPT BioRobotics, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on PROCEPT BioRobotics and raised the price target from $74 to $95, indicating confidence in the company's future performance.
September 03, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has maintained a Buy rating on PROCEPT BioRobotics and increased the price target from $74 to $95, suggesting a positive outlook for the company's stock.
The increase in the price target from $74 to $95 by Truist Securities indicates a strong positive sentiment towards PROCEPT BioRobotics' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100